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Abstract: As with other neurodegenerative diseases, neuro-
logic and nutritional elements may interact affecting each
other in Parkinson’s disease (PD). However, the long-term
effects of such interactions on prognosis and outcome have
not been given much attention and are poorly addressed by
current research. Factors contributing to the clinical condi-
tions of patients with PD are not only the basic features of
PD, progression of disease, and the therapeutic approach
but also ﬁber and nutrient intakes (in terms of both energy
and protein content), ﬂuid and micronutrient balance, and
pharmaconutrient interactions (protein and levodopa). During
the course of PD nutritional requirements frequently change.
Accordingly, both body weight gain and loss may occur
and, despite controversy, it seems that both changes in
energy expenditure and food intake contribute. Nonmotor
symptoms play a signiﬁcant role and dysphagia may be re-
sponsible for the impairment of nutritional status and ﬂuid
balance. Constipation, gastroparesis, and gastro-oesophageal
reﬂux signiﬁcantly affect quality of life. Finally, any
micronutrient deﬁciencies should be taken into account.
Nutritional assessments should be performed routinely. Opti-
mization of pharmacologic treatment for both motor and
nonmotor symptoms is essential, but nutritional interventions
and counseling could and should also be planned with
regard to nutritional balance designed to prevent weight loss
or gain; optimization of levodopa pharmacokinetics and
avoidance of interaction with proteins; improvement in gas-
trointestinal dysfunction (e.g., dysphagia and constipation);
prevention and treatment of nutritional deﬁciencies (micro-
nutrients or vitamins). A balanced Mediterranean-like
dietary regimen should be recommended before the intro-
duction of levodopa; afterward, patients with advanced dis-
ease may beneﬁt considerably from protein redistribution
and low-protein regimens.  2009 Movement Disorder Society
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Several studies have shown a close relationship
between nutritional status and neurodegenerative dis-
eases. Similar evidence is shared also by Parkinson’s
disease (PD).1–15
PD is a chronic neurodegenerative disorder that is
due mainly to the progressive degeneration of the ni-
grostriatal dopaminergic pathway.16 Bradykinesia, rest-
ing tremor, rigidity, curved posture, shufﬂing gait, and
postural instability are its cardinal symptoms and signs,
which, together with the long-term complications of
dopaminergic treatment (motor blocks and dyskine-
sias), progressively lead to severe disability.17 Along
with this, not only motor but above all nonmotor com-
plications, together with some available treatments,
contribute substantially to the changes in nutritional
status during the course of the disease.8,13,14,18–24 Thus,
adjustment of nutritional intake should always be taken
into consideration.
It is now accepted that a nutritional assessment
should be included in the work-up of patients with PD.
Nutritional advice may contribute to the amelioration
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of symptoms and health-related quality of life (e.g.,
controlled-protein dietary regimens for patients with
motor ﬂuctuations).25,26 The objective of this review is
to point out the major nutritional issues that should be
taken into consideration in the management of patients
with PD and to describe the nutritional therapeutic
options that are available. The issues are discussed
from a clinical rather than a pathophysiologic
perspective. Few clinical trials have been performed on
nutritional issues in PD, and so most of the therapeutic
options are based on indirect evidence and on specula-
tion. The inadequacy of clinical evidence will be
stressed whenever appropriate and suggestions for
further research will be made.
BODY WEIGHT
As in other neurodegenerative disorders, such as
Alzheimer’s syndromes,1 longitudinal studies have sug-
gested that middle-age adiposity, especially when it
involves the visceral body fat compartment, may be a
risk factor for PD2,3,5 (Table 1). However, studies
investigating the independent effect of the complica-
tions of obesity, such as diabetes and hypercholestero-
lemia, as risk factors for PD have provided inconsistent
results (Table 2).28–34 Other studies have reported that
increase in body mass index [BMI 5 weight (kilo-
gram)/height (square meter)] is unrelated to PD.5,27
The lack of consistency of these studies may be due to
the strong confounding effects of dietary factors or
weight loss preceding clinical diagnosis.5 However,
during the course of patients with PD may experience
both weight loss and gain (Fig. 1). This is consistent
with the results of a recent study in the Italian popula-
tion, which revealed that the prevalence of obesity
among patients with PD is about 50% higher than that
in the general reference population.7
Weight Loss
Progressive weight loss down to overt undernutrition
is a major feature of PD progression.6,12,35,36 Weight
loss, especially fat mass loss,20,37 is believed to be a
continuous process that starts several years before di-
agnosis.37 It worsens as the disease progresses, along
with poor motor control (ﬂuctuations) and poor
response to treatment.6–8 The observation that weight
loss frequently precedes the diagnosis, despite a tend-
ency to increase energy intake, supports the hypothesis
that it is mainly due to an increase in energy expendi-
ture.18,37–39 However, it is reasonable to argue that
both energy intake and expenditure contribute to
weight loss during the course of the disease.
Resting energy expenditure studies by indirect
calorimetry have reported that calorie consumption is
signiﬁcantly increased in both untreated and optimally
treated patients with PD.19,20,38 Rigidity and dyskine-
sias may be responsible for increases in energy
TABLE 1. Studies investigating the association between body weight, adiposity, and the risk for Parkinson’s disease (PD)
Study (nation)
Follow-up
duration, yr Sample size [cases] Reported evidence
Hu et al.
(Finnish)2
18.8 22.367 males,
23.439 females [272M:254F]
Increasing BMI was associated with
higher PD risk in both sexes; the
association with early-onset PD (aged at
diagnosis <65 yr) was even stronger
Abbott et al.
(Japanese Americans)3
30 7.990 males [137] Increasing adiposity measured by triceps
skinfold thickness was associated with an
elevated risk of early-onset (age at diagnosis
<65 yr) and late-onset (aged at diagnosis >65 yr)
PD. Associations between BMI and subscapular
skinfold thickness were weaker
Chen et al.
(Americans)5
12–14 47.700 males,
117.062 females [249M: 202F]
In the overall study cohort, neither baseline BMI
nor early adult BMI nor body fat distribution
(WC and WHR) was associated with PD risk.
However, among never smokers the highest quintiles
of central fat distribution indexes were associated with
PD risk in both sexes
Logroscino et al.
(Americans)27
20 10.812 males [106M] In elderly subjects (mean cohort age at inclusion 67.7 yr),
increasing BMI was not associated with PD risk. This may
be due to weight loss preceding clinical diagnosis, as subjects
losing 0.5 units of BMI per decade had a signiﬁcantly
increased risk
BMI, body mass index; WC, waist circumference; WHR, waist-to-hip ratio.
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expenditure, but they cannot be considered to be the
sole cause of a highly negative energy balance (400
Kcal/day). Motor symptoms can frequently restrict
activities of daily living related to food intake, such as
cooking or shopping35; this supports the hypothesis
that reduced energy intake may also have a role.
Indeed, a recent 3-year longitudinal study showed that
impairment of nutritional status, assessed using the
Mini Nutritional Assessment tool, was mainly due to
poor nutritional habits.8 However, increasing energy
intake to compensate for the increase in energy
expenditure was not effective in preventing weight
loss. This indicates that other factors contribute to the
phenomenon (e.g., malabsorption).18,40
Decline in cognitive functions may also play a
role,1,12,36 because it can affect interest in food through
hyposmia and eating habits. Individuals with memory
impairment may forget to eat and physical disability
may impede feeding in the absence of a caregiver.1
Indeed, neurodegeneration and cognitive impairment
have been associated with poor nutritional status also
in PD.12,41
Weight Gain
Surgical procedures (pallidotomy, deep brain stimu-
lation) are associated with signiﬁcant weight
gain.22,23,42,43 A number of concurrent factors are
believed to contribute, especially disease improvement
and the resolution of levodopa (L-dopa)-related compli-
cations (dyskinesias).22,23,42 Increase in appetite has
been reported44 and hormonal (e.g., insulin and growth
hormone) balance may be restored (see Body Weight
and Metabolic Derangements section).6
Also dopamine agonists, such as pramipexole, may
produce weight gain mediated by similar mechanisms
to those described earlier (induction of compulsive eat-
ing or a positive effect on depressive symptoms) in
patients with PD with poor quality of life.21,44,45
Moreover, regardless of the treatment provided, also
abnormal neuroendocrine regulation (e.g., corticotro-
TABLE 2. Studies investigating the association between cardiovascular risk factors and the risk for Parkinson’s disease (PD)
Study (ethnicity)
Follow-up
duration, yr
Sample size
[cases] CV risk factor Reported evidence
Hu et al.
(Finnish)29
18 25.188 males,
26.374 females
[324M:309F]
Diabetes Increasing BMI was associated with higher
PD risk in both sexes; the association with
early-onset PD (aged at diagnosis <65 yr)
was even stronger
Driver et al.
(Americans)32
23 21.841 males [566] Diabetes Increasing adiposity measured by triceps skinfold
thickness was associated with an elevated risk of
early-onset (age at diagnosis <65 yr)
and late-onset (aged at diagnosis
>65 yr) PD. Associations between BMI and subscapular
skinfold thickness were weaker
Simon et al.
(Americans)30
23 50.833 males,
121.046 females
[264M:266F]
Diabetes Updated self-reported diagnosis of diabetes was unrelated
to increased PD risk
Hypertension Updated self-reported diagnosis of high blood pressure
(systolic >160 mmHg and/or diastolic >90 mmHg
and/or use of antihypertensive medications)
was unrelated to PD risk.
Total cholesterol Updated self-reported hypercholesterolemia was unrelated
to PD risk although this may modestly decline with
increasing blood cholesterol levels
Hu et al.
(Finnish)31
18 24.773 males,
26.153 females
[321M:304F]
Total cholesterol Increasing total cholesterol is associated with PD risk..
However, the association was inconsistent in subjects
aged ‡55 years at baseline. Ongoing chronic disorders
might have masked (reducing levels ?) the effect in
this subgroup.
de Lau et al.
(Dutch)34
9 2.654 males,
3.811 females
[46M:41F]
Total cholesterol In elderly subjects (mean age at inclusion 69.0 years)
the authors observed a dose-effect relationship
between increasing total cholesterol levels and
decrased risk of PD. In gender pre-speciﬁed subgroup
analyses the association was restricted to women
Huang et al.
(Japanese-Americans)33
9 3.233 males [41] LDL-cholesterol In subjects aged 71–75 years at inclusion, the authors
detected a dose-effect relationship between decreasing
LDL cholesterol levels and increased risk of PD.
The basis of this association needs to be clariﬁed
BMI, body mass index; WC, waist circumference; WHR, waist-to-hip ratio.
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phin-releasing hormone and orexin-related signaling
pathways) is believed to play a role in inducing weight
gain.46
Body Weight and Metabolic Derangements
Long-term L-dopa treatment, the mainstay of PD
management, induces hypersecretion of both insulin
and growth hormone (GH).47 This hormonal derange-
ment can trigger a lipolytic cycle that is thought to be
responsible for the increase in basal metabolic rate48
and weight loss. Disruption of this derangement due to
neurosurgical procedures or L-dopa dosage reduction
could explain weight gain. Glucose intolerance, which
is closely related to adiposity,4 is often found in
PD49,50 and may also be a risk factor for PD.29 The
true interrelationship among these factors is not known.
It is reasonable to argue that genetic and environmental
factors interact during ageing and that glucose intoler-
ance might occur before the onset of PD or become
evident after the introduction of L-dopa.
The association between weight changes/control and
glucose intolerance/diabetes in PD, and the effect on
outcome have never been investigated. Routine screen-
ing for glucose intolerance seems to be advisable.
Weight Changes and Implications for Health Status
The effect of weight changes on patient prognosis
and disease progression is still unknown. Non-PD dis-
ease-related malnutrition has a negative impact on the
prognosis of the patient,51 and in some neurodegenera-
tive diseases, such as Alzheimer’s disease, it may be
associated with accelerated progression of the
disease.10 It cannot be excluded that a high initial body
weight may counterbalance progressive weight loss,
thus slowing physical deterioration. Low BMI certainly
is associated with a reduction in bone mineral mass
FIG. 1. Possible natural history of body weight in patients with PD.
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density, and a high risk of fractures that can be sec-
ondary to vitamin D deﬁciency.52,53 Noteworthy is the
quality of weight gain in patients with PD undergoing
deep brain stimulation, which seems to differ according
to gender, with men gaining primarily fat-free mass
and women adipose tissue.42 Abdominal fat mass sig-
niﬁcantly increases after neurosurgery in both
sexes,22,42 and the prevalence of adverse fat distribu-
tion is high in PD7—a reason for concern given the
risk of complications, such as cardiovascular disease,
diabetes, and dementia syndromes, related to this body
fat compartment.4
Studies exploring changes and abnormalities in
cardiometabolic parameters have not been performed.
Overweight in PD seems to be associated with sig-
niﬁcant rates of dyslipidemia (52.2%), arterial
hypertension (28.3%), and impaired glucose control
(17.5%).7
GASTROINTESTINAL DYSFUNCTION
Gastrointestinal dysfunction may affect the patient’s
well-being, treatment optimization, and nutritional bal-
ance (Fig. 2). Given the difﬁculty in performing repeti-
tive movements and the presence of jaw tremor and/or
rigidity, chewing may be impaired, also on account of
concurrent tooth damage.54 Prolonged feeding proce-
dures and fatigue, secondary also to difﬁculties in
swallowing55 can lead to meal interruption and inad-
equate food intake. Progressive limitation or avoidance
of some products may lead to deﬁciencies, initially in
micronutrients and subsequently in energy.35
Dysphagia
Dysphagia is believed to play a role in weight
loss.6,8,37,56 However, according to some authors
it makes a minor contribution, because it usually
occurs in the advanced phases of the disease,57
although sometimes it is present at onset.58 Various
investigations (electrophysiology, manometry, video-
ﬂuorography) have detected functional alterations of
both oropharyngeal and oesophageal motility in about
60 to 80% of patients; such alterations may be asymp-
tomatic.58–62 The risk of aspiration due to upper oeso-
phageal dysmotility should be taken into account and
routine assessment of such abnormalities may be
suggested. Simple tools, based on clinical parameters
(BMI, Hoehn and Yahr stage, drink and food retention
in the mouth) or questionnaires addressing self-
reported perception of swallowing disturbances, have
recently been proposed for patient assessment, pro-
vided that their sensitivity and speciﬁcity (‡80%) are
adequate. Their use in clinical practice should be
extensively investigated and validated.63,64
Dysphagia may be for both solids and liquids. The
former may be responsible for energy imbalance,56 the
latter is usually associated with dehydration and risk of
aspiration, as well as with social and psychological dis-
comfort, mainly due to saliva retention in the mouth
associated with drooling.64,65
Regarding the pathophysiology of oesophageal dys-
function, it is believed that the underlying neurodege-
nerative mechanisms in the central and the peripheral
nervous system such as the brainstem nuclei and Auer-
bach’s and Meissner’s plexuses, are similar.108 The ini-
tial location and exact timing of this pathological pro-
cess are still unknown. The existence of a continuous
chain of susceptible neurons, extending from the en-
teric to the central nervous system, has recently been
demonstrated. The evidence supports the hypothesis
of a centripetal progression of the neurodegenerative
process.67
The involvement of oesophageal motility results not
only in impaired peristalsis but also in abnormalities in
lower sphincter activity contributing to gastro-oesopha-
geal reﬂux. This complication is more likely to occur
in the presence of gastric dysfunction.68
Gastric Dysfunction
Impaired gastric emptying is commonly reported in
both early and advanced patients with PD.69,70 It seems
to be related to severe motor function impairment and
motor ﬂuctuations, typical of disease progression,70 but
the basis of the association is not fully understood.
Delayed gastric emptying may prolong the exposure of
L-dopa to dopa decarboxylase in the gastric mucosa
and delay the arrival of the drug into the duodenum,
reducing its absorption from the gut and, consequently,
its efﬁcacy.71 However, it cannot be excluded that
poor motor control and gastric dysfunction in advanced
PD are simultaneous manifestations of a neurodegener-
ative process affecting both the central (dorsal motor
nucleus of the vagal nerve) and peripheral nervous sys-
tem.58,67,69 This hypothesis is consistent with the
results of a trial reporting that L-dopa ethylester, a very
soluble L-dopa prodrug that passes through the stomach
very rapidly, does not provide any advantage in reduc-
ing total daily time in ON.109 Finally, alterations in
gastric and intestinal motility may be associated with
abdominal distension, discomfort, nausea and early sa-
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tiety, and bloating may reduce enjoyment of food and
energy intake. Weight loss may be a consequence.
Small Intestine Dysfunction
Very little is known about small intestine function
in PD. Dopaminergic enteric activity is believed,
once again, to be involved. Changes in motility pro-
long orocaecal transit.58,72 Such changes might be
associated with bacterial overgrowth in the small
intestine and malabsorption due to both speciﬁc and
nonspeciﬁc alterations of the enterocyte brush border
membrane.48
Constipation
Constipation (less than three bowel movements per
week) is the most commonly reported (50–80%) gas-
trointestinal symptom in PD.13,27 It can occur during
both preclinical and clinical stages of the disease13,68,73
and worsens with disease progression.74 Barium studies
have shown that prolonged colon content transit time
is the physiological basis of both symptomatic and
asymptomatic constipation.75 Most patients experience
only mild discomfort and distension, but the risk of
life-threatening complications, such as megacolon and
pseudo or true obstruction resulting in bowel perfora-
tion should be taken into account and prevented.75
Dysmotility may be related to poor ﬁber and ﬂuid
intake or reduced physical activity.75,77 Some authors
point out that the neurodegenerative process in the
enteric nervous system may be a potential target for
future therapies.58,78,79
Therapeutic Approaches
Gastrointestinal dysfunction responds poorly to cur-
rent treatment (both medical and surgical) for motor
symptoms. Signiﬁcant improvement seems to be
achievable only in the oral and pharyngeal phases of
swallowing, which depend mainly on the function of
the medullary pattern generator network and the
outﬂow of the basal ganglia.80–82
The efﬁcacy of alternative pharmacological treat-
ments has been investigated, but few clinical trials
have been performed. Some medications have been
withdrawn, and the use of others has been discouraged
after initial testing due to adverse effects.
To improve dysphagia, no universal approach is
available. The optimization of motor symptom con-
trol should always be given priority, and both surgi-
cal and pharmacological options have been investi-
gated in regard to this. L-dopa and apomorphine can
improve the early phases (oral and pharyngeal) of
deglutition, also by restricting total swallowing
time.81,82 The percutaneous injection of botulinum
toxin or the resection of the cricopharyngeal muscle
have been considered only in selected patients83,84
and beneﬁt from neurosurgical stimulation have been
reported.81
The use of prokinetic agents has been suggested
for the management of delayed gastric emptying. To
date, only domperidone by oral route has proved to
be both effective and safe.58 Unlike metoclopramide,
another D2 (dopamine type 2) receptor blocker (an-
tagonist), it is less likely to cross the blood–brain
barrier and exacerbate parkinsonism. A similar
adverse effect has been reported with the use of cis-
apride and the main concern with this drug is related
to the risk of fatal arrhythmias and sudden
death. The use of prokinetics in the treatment of
constipation is doubtful.
Irritant laxatives are reserved to selected patients,
whereas stool softeners, such as polyethylene glycol
solutions (Macrogol) or lactulose, are more widely
used and better tolerated.85,86 There is evidence sup-
porting the use of probiotics and prebiotics in the el-
derly,87 but their use has never been investigated in
patients with PD. Finally, a recent pilot randomized,
controlled trial has suggested that a 5-HT4 (5-hy-
droxytryptamine subtype-4 receptor) partial agonist
(tagaserod) is both efﬁcacious and safe.88
Based on the considerations above, there are few
pharmacological options for the management of gastro-
intestinal dysfunction. Nevertheless, a number of nutri-
tional recommendations could be provided to improve
symptoms, discomfort and quality of life. The sugges-
tions rest on limited evidence mostly collected in other
populations of patients because clinical trials in PD are
still lacking.
NUTRITIONAL TREATMENT:
PRESENT AND FUTURE
Body weight control is crucial in our century, as the
consequences of malnutrition, both in terms of excess
and deﬁciency, are now well known. In patients with
PD, this could be achieved through adjustments
in nutritional intake, designed to improve motor and
nonmotor symptoms at the same time.
At present, there is no evidence to support or refute
the efﬁcacy of nonpharmacological nutritional therapy
for gastrointestinal dysfunction, which has proved to
be a complication associated with impaired quality of
life and nutritional status.5,85,90,94
1886 M. BARICHELLA ET AL.
Movement Disorders, Vol. 24, No. 13, 2009
Options for Dysphagia
Thickening procedures (e.g., for beverages and
soups) are generally recommended to increase ﬂuid
intake and to prevent aspiration pneumonia.89,90 Pos-
tural arrangements may also be useful. A large
randomized clinical trial, comparing the impact of
three interventions (chin-down posture and nectar-or
honey-thickened liquids) on liquid aspiration in PD,
and dementia patients has been published. Unfortu-
nately, deﬁnitive conclusions could not be drawn, nei-
ther about the superiority nor about the usefulness of
any procedure due to the lack of a no-treatment control
group.95 Texture-modiﬁed diet and the use of thick-
ened whole-formulations and ready-to-eat foods could
be taken into account to obtain better timing and safer
swallowing in patients with PD.89,90,95 A dietician
should monitor the effectiveness of the measures and
the severity of symptoms. Long-term inability to
achieve adequate nutrition is an established indication
for gastrostomy.93
Options for Gastric and Intestinal Dysfunction
Theoretically the nutritional management of gastric
dysfunction may result in several beneﬁts, such as
better L-dopa absorption and dosage reduction. The
pattern of gastric emptying may depend on meal com-
position (macronutrients) with fats and high-ﬁber foods
usually producing a delay.96,97
Changes in requirements may be rapidly adapted by
adjusting fat intake. However, high quality carbohy-
drates (starch) should be preferred, in view of their
effect on glucose tolerance.98
Fiber plays an important role in the management of
constipation and adequate consumption, at least 30 to
35 g daily, together with appropriate ﬂuid intake (at
least 1,500 mL daily) could be encouraged.73,86 Moder-
FIG. 2. Major gastrointestinal problems of patients with PD.
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ate fat and adequate ﬁber intake could be beneﬁcial
also for gastroesophageal reﬂux.99
Physical activity can increase bowel movements and
reduce reﬂux episodes,86,92 producing beneﬁts also
with regard to body weight, physical functions, health-
related quality of life, mood, strength, balance, and
gait speed. This practice could be proposed to patients
with PD but optimal exercise interventions (duration
and components) for the various disease’s stages have
not been established.100
Dietary Management of L-dopa-Treated Patients
Dietary neutral aminoacids and L-dopa compete for
transportation through a speciﬁc active-transport
system in the small intestine and at the blood–brain
barrier. The consequences of this competition are sub-
optimal clinical response, especially motor block.
Accordingly, diet manipulation focused on protein
intake could be considered. A diet with a normal pro-
tein content (15% of total energy) can be proposed to
patients in the initial stages of PD, whereas low-protein
and protein-redistribution dietary regimens (10% of
total energy) are more suitable for patients with PD
with advanced disease. These are based on the
restriction of the protein content of breakfast and lunch
and the consumption of a high-protein meal in the
evening.101
Patients are told to take their medication about
30 minutes before meals to maximize absorption.
Nevertheless, there is evidence suggesting that the die-
tary habits of patients with advanced PD and/or motor
ﬂuctuations should always be checked, as usual protein
intake often is 50% higher than the recommended daily
allowance (1.2 vs 0.8 g/kg ideal body weight).102
Patients should be monitored to avoid L-dopa over-
dose-related side effects.25 Moreover, long-term adher-
ence to this kind of regimen may induce weight loss
and nutritional deﬁciencies (e.g., protein, calcium, iron,
phosphorus, riboﬂavin, niacin).25,26 Logistic difﬁculties
and poor palatability have been also pointed out.103
These shortcomings appear to have been overcome by
the use of low-protein foods designed for patients with
chronic renal failure.26
Micronutrients
The evidence related to micronutrients is still
limited. Deﬁciencies in micronutrients seem to be asso-
ciated with eating difﬁculties and to occur before deﬁ-
ciencies in energy and protein. Low plasma levels of
some of them, such as iron, zinc, vitamins A and E
may be secondary to both reduced intake and increased
requirements due to oxidative stress.27 Low intakes of
antioxidant vitamins (e.g., A, C, and E) might increase
the risk of PD, but intervention studies do not support
the use of oral supplements.104 Folate may be given to
patients with L-dopa-related hyperhomocysteinemia to
counteract the hypothetical related risk of heart
disease, stroke and dementia.105 However, there are no
studies demonstrating an increased risk of vascular
disease in patients with PD with high homocysteine
levels, whereas very recent case–control studies have
reported conﬂicting associations with cognitive impair-
ment.106,107 Dietary regimens should also cover
calcium and vitamin D requirements.53
General Dietary Advice
The long-term follow-up of the patient with PD should
include assessments designed to address all the issues
discussed earlier. An algorithm for the dietary manage-
ment of patients with PD is proposed in Figure 3.
Regular physical activity is advisable. Before the
introduction of L-dopa, a balanced Mediterranean-like
diet model could be proposed.110 After the introduction
FIG. 3. A potential nutritional treatment pyramid for patients with
PD in relation to stage of disease.
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of L-dopa, the protein-redistribution dietary regimen
can improve its absorption. In the later stages of the
disease, patients could beneﬁt from the introduction of
low-protein products (rusks, bread, pasta, and other
snacks). Exact amounts of food can be prescribed to
induce body weight gain or loss. In the presence of
overt malnutrition or the risk of its development, the
use of energy-dense oral nutritional supplements
designed for renal patients may be taken into account,
as well as texture-modiﬁed diets and thickening
agents for concurrent dysphagia. Finally, when oral
feeding cannot maintain adequate energy intake any
longer, percutaneous endoscopic gastrostomy is clearly
indicated.93
CONCLUSIONS
The impact of nutritional management on the course
of the disease has not been elucidated and should be
investigated (Table 3).
Optimization of pharmacologic treatment for both
motor and nonmotor symptoms is essential. Nutritional
interventions and counseling should be planned at the
same time with regard to the following.
c Nutritional balance designed to prevent body weight
changes
c Optimization of L-dopa pharmacokinetics by avoiding
interaction with nutrients, such as dietary proteins
c Improvement in gastrointestinal dysfunction, such as
dysphagia, gastroesophageal reﬂux, constipation
c Prevention, detection, and treatment of nutritional
deﬁciencies, especially of micronutrients and vita-
mins
Most of the proposed options are based on indirect
evidence. Adequately designed ad hoc studies are
needed to provide evidence supporting current sugges-
tions and hypotheses.
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